Next Article in Journal
Surgical treatment of humeral metastatic tumors
Previous Article in Journal
Cardiovascular magnetic resonance imaging for detection of myocardial viability in chronic ischemic left ventricular dysfunction
Medicina is published by MDPI from Volume 54 Issue 1 (2018). Articles in this Issue were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence. Articles are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Lithuanian Medical Association, Lithuanian University of Health Sciences, and Vilnius University.
Open AccessArticle

Safety and efficacy study of the recombinant granulocyte colony-stimulating factor for prevention of neutropenia and neutropenia-related complications in women with metastatic breast cancer receiving docetaxel/doxorubicin

1
Department of Oncology
2
Department of Theoretical and Clinical Pharmacology, Kaunas University of Medicine
3
Institute of Oncology, Vilnius University
4
Institute for Biomedical Research, Kaunas University of Medicine
5
Contract Research Organisation “Biomapas”, Lithuania
*
Author to whom correspondence should be addressed.
Medicina 2009, 45(8), 600; https://doi.org/10.3390/medicina45080078
Received: 23 March 2009 / Accepted: 6 August 2009 / Published: 11 August 2009
Background. We evaluated efficacy and safety of recombinant granulocyte-colony stimulating factor (rGCSF) used as primary prophylaxis to prevent neutropenia and neutropenia-related complications induced by docetaxel and doxorubicin chemotherapy in patients with metastatic breast cancer.
Patients and methods
. Three centers in Lithuania enrolled 36 patients who received rGCSF (5 μg/kg/d) on day 2 of each 21-day chemotherapy with docetaxel 75 mg/m2 and doxorubicin 50 mg/m2 (AT) starting in the first cycle. Treatment regimen was repeated for up to six cycles.
Results
. Leukocytosis, bone pain, and headache were the most frequent adverse events, with incidence rates of 22%, 19%, and 8%, respectively. Adverse events were typical for rGCSF in this patient population. Overall incidence rate of febrile neutropenia was 14%. The mean duration of febrile neutropenia episodes across cycles was 2.14 days. Incidence of chemotherapy delay was 2%. There was no reduction in chemotherapy dose due to expected toxicity or side effects. Intravenous antibiotics for the treatment of febrile neutropenia were needed in 19% of cases. Quality-of-life assessment shows a significant improvement in emotional functioning and a significant decrease in pain score. The efficacy profile of rGCSF observed in the present study was comparable with that of other rGCSF products previously described in the published scientific literature.
Conclusions
. The primary prophylaxis of neutropenia and its complications by rGCSF was safe and effective for women with metastatic breast cancer who received chemotherapy with docetaxel and doxorubicin.
Keywords: breast cancer; recombinant granulocyte-colony stimulating factor; docetaxel and doxorubicin; adverse events; febrile neutropenia breast cancer; recombinant granulocyte-colony stimulating factor; docetaxel and doxorubicin; adverse events; febrile neutropenia
MDPI and ACS Style

Liutkauskienė, S.; Sveikata, A.; Juozaitytė, E.; Characiejus, D.; Juodžbalienė, E.; Kregždytė, R.; Fokas, V. Safety and efficacy study of the recombinant granulocyte colony-stimulating factor for prevention of neutropenia and neutropenia-related complications in women with metastatic breast cancer receiving docetaxel/doxorubicin. Medicina 2009, 45, 600.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop